Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Russell Young

Dermatology Salem, OR Medical Doctor

NPI 1144285529 CMS profile 233501

1793 13Th St Se, Salem, OR 97302

Open in the dashboard

General payments

$8,488

311 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Russell Young of Salem, OR is reported in the CMS Open Payments database as having received $8,488 across 311 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18 1
2024 General $919 32
2023 General $1,828 78
2022 General $1,979 85
2021 General $1,277 54
2020 General $1,605 24
2019 General $863 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Russell Young
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Russell Young were reported at $18. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Russell Young Dermatology median Middle half National median
2019 $863 $454 $129–$1,240 $163
2020 $1,605 $235 $81–$756 $114
2021 $1,277 $377 $108–$1,108 $132
2022 $1,979 $514 $143–$1,391 $149
2023 $1,828 $607 $159–$1,674 $160
2024 $919 $751 $204–$1,903 $164
2025 $18 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,582 108 payments
  2. Janssen Biotech, Inc. $1,473 62 payments
  3. Barco, Inc. $956 1 payment
  4. Abiomed $777 33 payments
  5. Lilly USA, LLC $435 20 payments
  6. Genzyme Corporation $420 20 payments
  7. Sun Pharmaceutical Industries Inc. $274 9 payments
  8. Novartis Pharmaceuticals Corporation $250 13 payments
  9. Amgen Inc. $246 9 payments
  10. Janssen Scientific Affairs, LLC $229 2 payments
  11. Other $847 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,004 304 payments
  2. Consulting Fee $956 1 payment
  3. Education $528 6 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $1,540 53 payments
  2. SKYRIZI $1,505 64 payments
  3. RINVOQ $1,032 34 payments
  4. Impella $777 33 payments
  5. DUPIXENT $524 22 payments
  6. HUMIRA $456 30 payments
  7. TALTZ $413 19 payments
  8. ILUMYA $274 9 payments
  9. STELARA $230 14 payments
  10. Otezla $220 8 payments
  11. Other $1,870 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$305,218

Of which drugs: $6,536

Medicare patients

5,288

Average age 76

Services billed

13,236

2,542 women, 2,746 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 38%
Ischemic heart disease 20%
Diabetes 19%
Atrial fibrillation 18%
Chronic kidney disease 17%
Cancer 15%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 12 3,400 $4,446

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $318
$318 — —
TREMFYA
  • Janssen Biotech, Inc. $250
$250 — —
RINVOQ
  • AbbVie, Inc. $186
$186 — —
Otezla
  • Amgen Inc. $45
$45 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

311 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record